| Selpercatinib Basic information | |
| Product Name: | LOXO-292 |
| Synonyms: | CPD2206;LOX-292;LOXO-292;LOXO292;LOXO292;LOXO-292,Selpercatinib;Selpercatinib(LOXO-292);6-?(2-?Hydroxy-?2-?methylpropoxy)?-?4-?[6-?[6-?[(6-?methoxy-?3-?pyridinyl)?methyl]?-?3,?6-?diazabicyclo[3.1.1]?hept-?3-?yl]?-?3-?pyridinyl]?pyrazolo[1,?5-?a]?pyridine-?3-?carbonitrile;Pyrazolo[1,5-a]pyridine-3-carbonitrile,6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-;LOXO-292USP/EP/BP |
| CAS: | 2152628-33-4 |
| MF: | C29H31N7O3 |
| MW: | 525.6 |
| EINECS: | 207-854-9 |
| Product Categories: | Bioactive molecules; Pharmaceutical and chemical raw materials; Inhibitors; Small molecule; Small molecule inhibitors; GS; Chemical Industry; Pharmaceutical raw materials; Active pharmaceutical ingredients; API; Standard products; Raw materials and intermediates; raw material |
| Mol File: | 2152628-33-4.mol |
| Introduction | Secatinib is an effective Src inhibitor with an IC50 of 2.7 nM, and also acts effectively on c-Yes, Fyn, Lyn, Blk, Fgr, and LcChemicalbookk; The activity of Abl and EGFR (L858R and L861Q) is slightly lower. Secatinib is the first inhibitor to act on the Src pathway in human tumor tissue. |
| Selpercatinib Chemical Properties | |
| Density | 1.36±0.1 g/cm3(Predicted) |
| Acidity coefficient (pKa) | 14.00±0.29(Predicted) |
| Storage | Store at -20°C |
| form | Crystalline solid |
| color | White to off white |